RARE

16.6303.43%
SS

Shehnaaz Suliman

Independent Director

Dr. Shehnaaz Suliman, M.B.A., M.D., M.Phil., is Independent Director of Ultragenyx Pharmaceutical Inc. from February 2019. Dr. Suliman is Independent Director of 10x Genomics, Inc. from August 2019. Dr. Suliman is Director of ReCode Therapeutics, Inc. from 2025 and served as its President and Chief Executive Officer until August 2026 and serves as its Executive Chairman since August 2026. Dr. Suliman was CEO & Director of ReCode Therapeutics, Inc. from January 10, 2022 to 2025. Dr. Suliman was Chief Executive Officer of ReCode Therapeutics, Inc. from January 2022 to January 10, 2022. Dr. Suliman was Adjunct Partner Board of IndieBio. Dr. Suliman was Senior Vice President of Corporate Development & Strategy of Theravance Biopharma, Inc. from July 31, 2017 to March 01, 2019. Dr. Suliman was employed at Theravance Biopharma, Inc. from July 31, 2017 to March 01, 2019. Dr. Suliman was Advisor of Alector, Inc. from September 2021 to December 31, 2021. Dr. Suliman was President, COO & Interim Chief Business Officer of Alector, Inc. from February 01, 2021 to September 2021. Dr. Suliman was President & COO of Alector, Inc. from December 2019 to February 2021. Dr. Suliman was employed at Alector, Inc. from December 2019 to December 31, 2021. Dr. Suliman has M.Phil. in Developmental Studies from University of Oxford, M.B.A. from University of Oxford, M.D. from University of Cape Town Medical School.

Positions